As you may remember, the Food and Drug Administration indicated that, upon advice of an advisory committee, it will rescind its approval for Avastin® for treatment of metastatic breast cancer. Genentech® has requested a hearing to reconsider the decision, and that hearing is currently scheduled for the end of June. See my list below for previous posts with further information.
It is not surprising that patients with MBC who have experienced an excellent response to Avastin are worried. In fact, the husband of one patient has taken a leave of absence from his job in Michigan in order to devote time and energy to support the continuance of the FDA’s approval for Avastin’s use for metastatic breast cancer. In addition to traveling with his wife Arlene to Washington DC to lobby for the continued approval of Avastin, Terry Kalley has created an online site Freedom of Access to Medicine, where supporters can click on links to make a donation, sign a petition, sign up to protest at the hearings or receive updates or to tell your own story about your success with Avastin. FAMED also uses both Twitter and FaceBook accounts to spread the word.
Read more at this article in the Wall Street Journal.
My previous relevant blog entries in descending order:
- Medicare continues to pay for Avastin pending hearing outcome
- FDA grants Avastin hearing 6/28-29/2011
- update: Avastin decision postponed
- Avastin again in news: fed ready to consider rescinding approval for MBC
- committee recommends Avastin approval be revoked for advanced breast cancer
- Avastin disapproved for breast cancer treatment
5 6 7 8
© 2004—2011 Donna Peach. All rights reserved.